Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Change in Receivables (2016 - 2025)

Surgery Partners' Change in Receivables history spans 12 years, with the latest figure at $46.1 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 12.71% year-over-year to $46.1 million; the TTM value through Dec 2025 reached $53.8 million, down 25.38%, while the annual FY2025 figure was $53.8 million, 25.38% down from the prior year.
  • Change in Receivables for Q4 2025 was $46.1 million at Surgery Partners, up from $16.2 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $46.1 million in Q4 2025 and bottomed at -$8.8 million in Q1 2023.
  • The 5-year median for Change in Receivables is $13.4 million (2021), against an average of $12.0 million.
  • The largest annual shift saw Change in Receivables surged 975.0% in 2021 before it crashed 340.0% in 2023.
  • A 5-year view of Change in Receivables shows it stood at $13.7 million in 2021, then surged by 182.48% to $38.7 million in 2022, then decreased by 25.06% to $29.0 million in 2023, then surged by 41.03% to $40.9 million in 2024, then rose by 12.71% to $46.1 million in 2025.
  • Per Business Quant, the three most recent readings for SGRY's Change in Receivables are $46.1 million (Q4 2025), $16.2 million (Q3 2025), and -$3.7 million (Q2 2025).